Daclizumab
In the US, Daclizumab (daclizumab systemic) is a member of the drug class interleukin inhibitors and is used to treat Organ Transplant - Rejection Prophylaxis and Rheumatoid Arthritis.
US matches:
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
L04AA08,L04AC01
CAS registry number (Chemical Abstracts Service)
0152923-56-3
Chemical Formula
C6394-H9888-N1696-O2012-S44
Molecular Weight
144129
Therapeutic Category
Immunosuppressant
Chemical Name
Immunoglobulin G 1 (human-mouse monoclonal clone 1H4 þ-chain anti-human interleukin 2 receptor), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer
Foreign Names
- Daclizumabum (Latin)
- Daclizumab (German)
- Daclizumab (French)
- Daclizumab (Spanish)
Generic Names
- Daclizumab (OS: USAN, BAN, DCF)
- Ro 24-7375 (IS)
Brand Names
International Drug Name Search
Glossary
| Term | Definition |
|---|---|
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Click for further information on drug naming conventions and International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
